Physician profile
Temple Gupta
NPI 1508816265
$5,143.81
in general payments reported to CMS, 2019-2025
31 companies · $992 in 2025
The $992 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $789 · 2022: $1,054 · 2023: $1,142 · 2024: $1,168 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.49 |
| Education | $111.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,212.36 | 2021-2025 | Tysabri, Vumerity, Tysabri |
| Pfizer INC. | $702.38 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $539.29 | 2022-2025 | Ultomiris |
| Lilly USA, LLC | $333.75 | 2021-2025 | Kisunla, Amyvid, Zepbound |
| Abbvie INC. | $290.61 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $261.68 | 2021-2025 | |
| Lundbeck LLC | $206.30 | 2023-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $179.98 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.68 | 2022 | |
| Emd Serono, INC. | $140.01 | 2021-2025 | Mavenclad |
| Genentech USA, INC. | $104.65 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Teva Pharmaceuticals USA, INC. | $103.71 | 2021 | |
| Sk Life Science, INC. | $102.44 | 2021-2023 | |
| Argenx US, INC. | $93.73 | 2023-2025 | Vyvgart Hytrulo |
| Amgen INC. | $91.64 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $90.97 | 2024-2025 | Zeposia |
| Neurelis, INC. | $70.52 | 2022 | |
| Genzyme Corporation | $66.79 | 2022-2025 | |
| Cala Health, INC. | $63.73 | 2023-2025 | Cala Kiq, Cala Kiq, Cala Trio |
| Ucb, INC. | $49.84 | 2021-2022 | |
| Acorda Therapeutics, INC | $37.36 | 2022 | |
| Acadia Pharmaceuticals INC | $36.30 | 2023-2024 | Daybue, Nuplazid |
| Supernus Pharmaceuticals, INC. | $34.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.82 | 2025 | |
| Axsome Therapeutics, INC. | $21.39 | 2023 | Sunosi |
| Eisai INC. | $20.36 | 2025 | |
| Otto Bock Healthcare LP | $19.43 | 2021 | |
| Neurocrine Biosciences, INC. | $17.72 | 2025 | |
| Harmony Biosciences LLC | $15.90 | 2023 | Wakix |
| Metacel Pharmaceuticals LLC | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temple Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.